Iova stock jumps 31% amid FDA setback for rival, short squeeze buzz, and rising momentum for Amtagvi melanoma therapy.

Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

Fintel reports that on July 23, 2025, Barclays downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 725.97% Upside As of July ...

Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Northern Trust Corp (NTRS) is expected to report $2.05 for 2Q. Otis Worldwide Corp (OTIS) is expected to report $0.93 for 2Q. PROG Holdings Inc (PRG) is expected to report $0.74 for 2Q. Pacific ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ("Replimune or the "Company") (NASDAQ: REPL).

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

"REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% After FDA Response Letter -- BFA Law Announces Securities Fraud Investigation And Urges Investors To Contact The Firm >REPL" was published ...

The FDA has issued a complete response letter to Replimune indicating it is unable to approve the biologics license ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion will be paid up front. The acquisition rests on an ongoing phase I trial of ...